Last reviewed · How we verify
Prednisone+vincristine
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation, while vincristine is a vinca alkaloid that interferes with microtubule formation in the mitotic spindle, thereby inhibiting cell division.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation, while vincristine is a vinca alkaloid that interferes with microtubule formation in the mitotic spindle, thereby inhibiting cell division. Used for Acute lymphoblastic leukemia, Hodgkin's lymphoma.
At a glance
| Generic name | Prednisone+vincristine |
|---|---|
| Sponsor | Shanghai Children's Medical Center |
| Drug class | Corticosteroid + Vinca alkaloid |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Prednisone works by inhibiting the production of inflammatory cytokines and inducing apoptosis in immune cells. Vincristine, on the other hand, binds to tubulin and prevents the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Approved indications
- Acute lymphoblastic leukemia
- Hodgkin's lymphoma
Common side effects
- Nausea
- Vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |